

Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma

Brian Martin PhD¹, Christine Bailey, MPH¹, Matthew Goldberg, MD^{1,2}, Valentina Petkov, MD, MPH³, Robert Cook, PhD¹, Kyle Covington, PhD¹, Sarah Kurley, PhD¹

¹Castle Biosciences, Inc., Friendswood, TX ²Icahn School of Medicine at Mount Sinai, New York, NY, ³National Cancer Institute, Surveillance Research Program, Bethesda, MD



Background

Despite a good overall prognosis for patients with a negative SLNB, 10-24% will experience recurrence or metastasis, and melanoma-specific survival (MSS) rates range from 82-99%.¹⁻⁴ A subset of these patients (stage IIB-IIC) are currently eligible for adjuvant therapy, though it is unclear which patients will benefit and which patients do not need therapy.⁵

The recent KEYNOTE-716 trial showed a benefit of adjuvant pembrolizumab in patients with stage IIB-IIC melanoma (9% RFS improvement), but 80% had an adverse event (16% grade 3 and higher), and 18% discontinued treatment due to adverse events.⁵

These data underpin a need for prognostic tools beyond clinicopathologic features to identify patients with high-risk tumor staging but low-risk tumor biology, or low-risk tumor staging but high-risk tumor biology, so that patients receive risk-aligned treatment.¹⁻²

Multiple prospective and independent studies have shown that the 31-GEP test is a consistent and independent predictor of survival outcomes in large populations of patients with stage I-III CM, and that clinicians use the 31-GEP to guide patient management decisions.^{3, 6-10}

Objective

In collaboration with the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program (covering 34% of the U.S. population during the study period) this study sought to:

Demonstrate the performance of the 31-GEP to identify patients with high-risk tumor biology in an unselected, clinically tested cohort of patients with a negative lymph node.


Methods

SEER cancer registries linked CM cases diagnosed from 2016-2018 to data for patients with CM who were tested with the 31-GEP (n=3,271). Linkage was mediated by Information Management Services (an Honest Broker for the SEER registries). A de-identified dataset was used for this analysis. A focused analysis of negative lymph node patients was performed.

Kaplan-Meier analysis with the log-rank test was used to analyze 3-year melanoma-specific survival (MSS). Multivariable Cox regression was used to identify factors associated with MSS.

Results

Figure 1. Using the 31-GEP in patients with a negative lymph node identifies those at highest risk of dying from their disease.




Patients with Class 1A results had higher 3-year MSS (Class 1A: 99.7%; Class 1B/2A: 97.8%; Class 2B: 91.8%, $p < 0.001$).

In the subset of patients with IIB-IIC disease (n=311), no Class 1A (0%, 0/38) patients died from melanoma compared with 6.7% (14/210; 8 IIB, 6 IIC) of Class 2B patients.

Table 1. Multivariable analysis demonstrates independent and significant prognostic information compared to traditional staging factors

Melanoma-specific survival	Multivariable HR (95% CI)
31-GEP Class 1A	Reference
31-GEP Class 1B/2A	5.76 (1.42-23.41)
31-GEP Class 2B	10.50 (2.55-43.28)
Age (continuous)	1.05 (1.02-1.08)
AJCC Stage IA	Reference
AJCC Stage IB	1.48 (0.37-6.01)
AJCC Stage IIA	3.93 (1.10-14.12)
AJCC IIB	3.24 (0.82-12.86)
AJCC IIC	4.58 (1.09-19.22)

Clinical Impact



Using the 31-GEP results to guide increased clinical management and surveillance for patients at high risk of melanoma-specific death may improve patient outcomes.

Conclusions

- In patients with a negative lymph node, the 31-GEP identifies patients more or less likely to die from their melanoma in the absence of adjuvant therapy, and the 31-GEP is a significant predictor of melanoma-specific death, even when accounting for substage.
- The 31-GEP can direct care to patients with high-risk tumor biology who are most likely to benefit from higher intensity management and away from those unlikely to benefit from adjuvant therapies to spare patients from adjuvant therapy-associated adverse events.

References

- Thomas, D. C. et al. Ann Surg Oncol 26, 2254-2262 (2019).
- Jones, E. L. et al. JAMA surgery 148, 456-61 (2013).
- Greenhaw, et al. Dermatol Surg 44, 1494-1500 (2018).
- O'Connell, E. et al. Mel Research 26, 66-70 (2016).
- Luke et al. Lancet, 399, 1718-1729 (2022)
- Hsueh, E. C. et al. JCO Precision Oncology 5, 589-601 (2021).
- Vetto, J. T. et al. Future Oncology 15, 1207-1217 (2019).
- Podlipnik, S. et al. J Eur Acad Dermatol Venereol 33, 857-862 (2019).
- Dillon, L. D. et al. SKIN J Cutaneous Med 2, 111-121 (2018).
- Berger, A. C. et al. Curr Med Res Opin 32, 1599-1604 (2016).

Acknowledgments & Disclosures

SK, CB, BM, MG, RC, and KC are employees and shareholders of Castle Biosciences, Inc. VP has no disclosures